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A B S T R A C T
Giant basal cell carcinoma (GBCC) is defined as a tumor 5cm or greater in diameter. They present less than 1% of all
basal cell carcinomas. We present a case of an 85-year-old male patient with a giant ulcerating tumor of the left forehead
(measuring 7x6cm). Under local anesthesia tumor was surgically excised. No involvement of the underlying periostal or
bone structure was noted. Pathohystological exam revealed the giant basal cell carcinoma, with free surgical margins.
Giant basal cell carcinomas are rare tumors and are usually result of a long duration and patient neglect. In comparison
to the ordinary basal cell carcinoma these tumors have a higher metastatic potential. Surgical resection with negative
surgical margin is the best possible treatment option.
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Introduction
Basal cell carcinoma (BCC) is the most common ma-
lignant skin tumor1,2. It usually appears as painless, no
healing ulcer or nodule on the sun-exposed parts of the
body. Sun exposure is the primary etiologic agent for the
development of the basal cell carcinoma. Risk is related
to skin type and the degree of exposure to sunlight, par-
ticularly UV-B radiation1. In addition to environmental
factors, host factors (e.g. genetic syndromes and immu-
nologic factors) play a critical role in the pathogenesis of
basal cell carcinoma. It has a particular predilection for
the upper two thirds of the face2. Basal cell carcinoma is
usually slow growing tumor, with incidence of
metastases less than 0.1%2. Four different clinico-patho-
logic types of basal cell carcinoma exist, each with dis-
tinct biologic behavior: undifferentiated, nodular or nod-
ular-ulcerative (more than 60% of all basal cell
carcinoma), superficial and morpheaform or sclerosing
basal cell carcinoma3. Giant basal cell carcinoma (GBCC)
is defined as a tumor 5 cm or greater in diameter. They
are very rare and present less than 1% of all basal cell
tumors2,4,5. Although the predilection site is also head
and neck region, some studies report other location (ex-
tremities, trunk)2,6–8. Giant basal cell carcinoma has
been associated with higher incidence of metastases2–4.
They are usually result of a long duration, patient ne-
glect and denial. With time they tend to ulcerate, with ar-
eas of necrosis and hemorrhage causing severe medical
problem to the patient. We present a case of an
85-year-old-male patient that has been admitted to the
Ear Nose and Throat Department due to a large tumor
mass of the left forehead region. We describe its clinical
course, treatment and final outcome.
Case Report
An 85-year-old male patient has been admitted to the
Ear Nose and Throat Department due to a giant ulcerat-
ing tumor of the left forehead. Over several years prior to
admittance the tumor has been slowly growing, with no
other symptoms. Several weeks prior to admittance tu-
mor became partially ulcerated with areas of hemor-
rhage and necrosis. Patient’s medical history revealed a
poor physical condition with a severe cardiovascular and
neurological deficit. Physical finding included a giant ul-
cerating tumor of the left forehead measuring 7x6cm in
diameter (Figures 1a–c). It was tightly attached to the
surface. No vital structures have been affected. There
was no clinical tumor lymph node involvement or distant
metastases present. Due to a poor physical condition of
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the patient he was not a suitable candidate for a surgical
procedure under the general anesthesia, thus we decided
to remove the tumor under the local anesthesia. Tumor
was surgically radically excised. No involvement of the
underlying periostal or bone structure was noted (Figure
1d). The defect was closed using the free tissue transfer
(Thiersch skin graft) from the left forearm (Figure 2).
Postoperative period was uneventful. Pathohistological
analysis revealed an ulcerated tumor mass measuring
7x6x3cm. Tumor consisted of solid infiltrative, epithelial
basal cells with palisade formation (Figure 3). Infiltra-
tion of the dermis was 1.2cm. Surgical margins were free
of any tumor tissue. Final diagnosis was giant basal cell
carcinoma. One year following the surgery the patient is
free of recurrent disease and the defect site is cosmetic-
ally acceptable.
Discussion
Giant basal cell cancers are rare tumors. Risk factors
associated with giant basal cell carcinomas are length of
time to presentation, patient neglect, previous treatment
and an aggressive histological type9–13. In the present
case the tumor was slowly growing over the years and pa-
tient requested medical attention at the time when tu-
mor became ulcerated with areas of hemorrhage and ne-
crosis, and has become a serious medical problem. The
predominant region for these tumors is head and neck2,9.
When compared to ordinary basal cell carcinomas these
tumors have an increased metastasis potential2. In the
present case the tumor was located on the left forehead
region. There was no local lymph node involvement or
any sign of metastases. When metastases are present
survival is significantly decreased. Metastasis develops
in 38.3% of patients despite optimal therapy14. The over-
all optimal cure rate is 61.7%14. Risk of recurrence is di-
rectly related to the initial tumor size. Radiation therapy
has been suggested as an alternative to surgical treat-
ment, especially for patient that are not candidates for
prolonged anesthesia15. In the present case the patient
was not a suitable candidate for a general anesthesia due
to a poor general medical condition. Giving the nature of
the tumor that did not include any vital structure and
that there was no metastases or local lymph node in-
volvement present, we decided to surgically remove the
tumor under local anesthesia, which was very well toler-
ated by the patient. Reconstructive option for this type of
tumor depends on the extent of the disease. It has to be
done with careful consideration for the surrounding
structures (e.g. eye-structures and hairline). The possi-
ble reconstructive options include the use of local flaps
(e.g. lateral forehead or Esser cheek rotation flap)15, free
flaps and tissue expansion. In our case after the tumor
has been removed and there was no involvement of the
deeper structures and with the respect for the poor gen-
eral patient’s condition we decided to close the defect
with the split-thickness skin graft (Thiersch) taken from
the left forearm. Postoperative period was uneventful
and this procedure gave a suitable postoperative cos-
metic result.
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Fig. 1a–b. Forehead skin tumor with areas of hemorrhage and
necrosis; 1c. Tumor after excision measuring 7x6 cm in diame-
ter; 1d. No visible periostal tumor involvement.
Fig. 2. Defect reconstruction with the split-thickness skin-graft
(Thiersch).
Fig. 3. Patohistological analysis of the tumor, hemalaun-eosin
staining x4.
Conclusion
Giant basal cell carcinomas are rare tumors and are
usually result of a long duration and patient neglect.
Compared to the ordinary basal cell carcinoma they have
a higher metastatic potential. Surgical resection with
negative surgical margin is the best possible treatment
option. Regular follow up is mandatory.
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GIGANTSKI BAZOCELULARNI KARCINOM ^ELA – PRIKAZ SLU^AJA
S A @ E T A K
Gigantski bazocelularni karcinom ko`e definira se kao tumor ko`e ve}i od 5 cm. Ovi tumori predstavljaju svega 1%
od svih bazocelularnih karcinoma ko`e. U radu prikazujemo slu~aj 85 godi{njeg bolesnika s velikom, ulcerativnom,
tumorskom tvorbom ko`e ~ela (veli~ine 7x6 cm). Tumor je uklonjen u lokalnoj anesteziji. Nije uo~eno {irenje tumora u
okolno tkivo. Patohistolo{ka analiza pokazala je da se radi o gigantskom bazocelularnom karcinomu ko`e. Gigantski
bazocelularni karcinomi ko`e izuzetno su rijetki tumori i naj~e{}e su rezultat vi{egodi{njega rasta i nebrige bolesnika.
U odnosu na obi~ni bazocelulurani karcinom ko`e, imaju ve}i metastatski potencijal. Radikalna kirur{ka ekscizija pred-
stavlja najbolji terapeutski postupak.
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